AstraZeneca (AZN) said Monday that Enhertu, in combination with pertuzumab, has been approved in the US as a first-line treatment for adult patients with unresectable or metastatic HER2 positive breast cancer.

The approval has been based on Destiny-Breast09 phase 3 study results that showed Enhertu in combination with pertuzumab reduced the risk of disease progression by 44% versus taxane, trastuzumab and pertuzumab, AstraZeneca said.

Enhertu is an antibody drug conjugate discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, the company said.

Shares of AstraZeneca were up nearly 2% in recent Monday trading.

Price: 91.54, Change: +1.71, Percent Change: +1.90